Sort
48,018 grants matching “immunotherapy”
Cytokines and T Cell Development
$1,198,875Scott Durum · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Validation of a novel 3D culture platform for TNBC treatment selection
$1,198,662Kyuson Yun · Methodist Hospital Research Institute · R01 · FY2025 · CA
Mechanisms of Effective Humoral Immune Responses to HIV-1
$1,198,484Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
EVALUATING HLA CLASS II EVOLUTIONARY DIVERGENCE AS AN IMMUNOTHERAPY-SPECIFIC KIDNEY CANCER BIOMARKER
$1,198,458Sloan-Kettering Institute For Cancer Research · · FY2021 · Defense Health Agency
First-in-class TREM-1 inhibitors in combination therapy for pancreatic cancer
$1,198,246Alexander B Sigalov · Signablok, Inc. · R44 · FY2020 · CA
Cell Production Facility Core
$1,197,564Mark Dudley · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Cell Prep Core
$1,197,564John Wunderlich · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
Immunologic Monitoring and Cellular Products Laboratory
$1,197,257Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P30 · FY2020 · CA
Mechanisms of Effective Humoral Immune Responses to HIV-1
$1,197,237Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,197,237Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation
$1,196,731Richard Johnson · Saros Therapeutics Inc · R44 · FY2023 · CA
Immune Escape in Human Cancer: Mechanisms and Therapeutic Implications
$1,196,407Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · P01 · FY2009 · CA
Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
$1,196,074Stuart L Schreiber · Broad Institute, Inc. · U01 · FY2020 · CA
Targeting vulnerabilities of therapy-resistant cancer cell states with small molecules
$1,196,073Stuart L Schreiber · Broad Institute, Inc. · U01 · FY2021 · CA
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,195,794Mark Connors · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform
$1,195,189Shawn Hingtgen · Univ Of North Carolina Chapel Hill · U01 · FY2021 · TR
Mechanisms Of Immune Mediated Restriction Of HIV Replication In LTNP
$1,193,247Mark Connors · National Institute Of Allergy And Infectious Diseases · ZIA · FY2014 · AI
Cancer Biology and Genetics
$1,193,000Harold Varmus · National Human Genome Research Institute · ZIA · FY2014 · HG
Combinational Immunotherapies to Amplify Vaccine Induced
$1,193,000Johns Hopkins University · U19 · FY2005 · CA
Targeting exploitable vulnerabilities in T-cell Lymphoma
$1,192,732Samuel Ng · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Immune Function and the Progression to Type 1 Diabetes
$1,192,398Mark A Atkinson · University Of Florida · P01 · FY2015 · AI
Immune Function and the Progression to Type 1 Diabetes
$1,192,397Mark A Atkinson · University Of Florida · P01 · FY2017 · AI
Clinical Vector for TCR Immunotherapy Targeted to Melanoma
$1,191,796Boro Dropulic · Lentigen Corporation · R44 · FY2010 · CA
Adenosine Receptor Agonists as an Immunotherapy for Biodefense
$1,191,560Peter B Ernst · University Of Virginia · U01 · FY2008 · AI
Immune Function and the Progression to Type 1 Diabetes
$1,191,074Mark A Atkinson · University Of Florida · P01 · FY2014 · AI